prochlorperazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2274	58-38-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: prochlorperazine mesylate prochlorperazine capazine chlormeprazine chlorperazine meterazin meterazine proazine prochlorpemazine prochlorperazin prochlorpromazine prochlorperazine maleate prochlorperazine edisylate prochlorperazine dimaleate prochlorperzine	A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) Molecular weight: 373.94 Formula: C20H24ClN3S CLOGP: 4.58 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 9.72 ALOGS: -4.53 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

prochlorperazine mesylate
prochlorperazine
capazine
chlormeprazine
chlorperazine
meterazin
meterazine
proazine
prochlorpemazine
prochlorperazin
prochlorpromazine
prochlorperazine maleate
prochlorperazine edisylate
prochlorperazine dimaleate
prochlorperzine

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Molecular weight: 373.94
Formula: C20H24ClN3S
CLOGP: 4.58
LIPINSKI: 0
HAC: 3
HDO: 0
TPSA: 9.72
ALOGS: -4.53
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
50	mg	P
0.10	g	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.83 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	15 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	22 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 23, 1956	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nausea	427.22	11.39	1701	54886	762477	55473003
Febrile neutropenia	406.18	11.39	515	56072	105030	56130450
Drug ineffective	335.56	11.39	262	56325	918727	55316753
Disease progression	284.16	11.39	433	56154	104740	56130740
Dehydration	254.83	11.39	520	56067	158305	56077175
Diarrhoea	237.22	11.39	1263	55324	637244	55598236
Vomiting	230.06	11.39	1049	55538	497179	55738301
White blood cell count decreased	224.31	11.39	431	56156	125559	56109921
Contraindicated product administered	172.16	11.39	3	56584	186283	56049197
Rheumatoid arthritis	170.58	11.39	86	56501	382518	55852962
Plasma cell myeloma	159.55	11.39	215	56372	46431	56189049
Platelet count decreased	159.53	11.39	339	56248	106044	56129436
Fatigue	158.34	11.39	1339	55248	787213	55448267
Death	148.32	11.39	707	55880	340719	55894761
Synovitis	147.41	11.39	3	56584	161302	56074178
Systemic lupus erythematosus	145.27	11.39	9	56578	180069	56055411
Arthropathy	140.16	11.39	18	56569	200257	56035223
Neutropenia	135.10	11.39	407	56180	157760	56077720
Constipation	114.98	11.39	454	56133	201489	56033991
Therapeutic product effect decreased	114.37	11.39	17	56570	169435	56066045
Malignant neoplasm progression	113.16	11.39	237	56350	73350	56162130
Joint swelling	110.94	11.39	78	56509	289722	55945758
Glossodynia	108.36	11.39	13	56574	152445	56083035
Asthenia	107.12	11.39	649	55938	342324	55893156
Toxicity to various agents	94.76	11.39	54	56533	224510	56010970
Pericarditis	89.16	11.39	5	56582	108918	56126562
Neutrophil count decreased	87.97	11.39	170	56417	49652	56185828
Decreased appetite	87.83	11.39	444	56143	218787	56016693
Blood magnesium decreased	82.28	11.39	79	56508	11795	56223685
Hospice care	77.80	11.39	58	56529	6122	56229358
Neovascularisation	74.87	11.39	31	56556	1018	56234462
Full blood count decreased	74.34	11.39	104	56483	23245	56212235
Neuropathy peripheral	74.26	11.39	250	56337	102643	56132837
Abdominal pain	73.36	11.39	478	56109	258327	55977153
Neoplasm progression	72.83	11.39	122	56465	31894	56203586
Therapeutic product effect incomplete	70.69	11.39	11	56576	106020	56129460
Drug intolerance	67.56	11.39	101	56486	264717	55970763
Pleural effusion	67.34	11.39	214	56373	85266	56150214
Condition aggravated	67.25	11.39	155	56432	344743	55890737
Gangrene	65.33	11.39	50	56537	5490	56229990
Thrombosis	64.52	11.39	167	56420	59260	56176220
Arterial occlusive disease	64.17	11.39	49	56538	5361	56230119
Carbohydrate antigen 125 increased	63.72	11.39	37	56550	2560	56232920
Wound	63.53	11.39	30	56557	138774	56096706
Infusion related reaction	63.29	11.39	70	56517	208861	56026619
Heart rate abnormal	62.89	11.39	45	56542	4458	56231022
Akathisia	58.88	11.39	57	56530	8595	56226885
Clostridium difficile infection	57.07	11.39	100	56487	27098	56208382
Swelling	56.84	11.39	96	56491	239675	55995805
Hepatic enzyme increased	54.61	11.39	55	56532	171329	56064151
Red blood cell count decreased	54.02	11.39	116	56471	36501	56198979
Lymphadenitis	53.88	11.39	35	56552	2960	56232520
Small intestinal obstruction	53.65	11.39	75	56512	16750	56218730
Thrombocytopenia	53.15	11.39	274	56313	135950	56099530
Treatment failure	52.80	11.39	56	56531	170336	56065144
Drug abuse	52.67	11.39	4	56583	67606	56167874
Lower respiratory tract infection	52.23	11.39	25	56562	114769	56120711
Cytokine release syndrome	51.42	11.39	59	56528	10816	56224664
Colitis	51.17	11.39	123	56464	41688	56193792
Discomfort	50.52	11.39	41	56546	141720	56093760
Pancytopenia	50.01	11.39	199	56388	88516	56146964
Pain	49.95	11.39	427	56160	662757	55572723
Completed suicide	48.58	11.39	38	56549	133795	56101685
Maternal exposure during pregnancy	46.68	11.39	74	56513	189479	56046001
Psoriatic arthropathy	44.36	11.39	10	56577	73998	56161482
Mobility decreased	44.36	11.39	22	56565	98969	56136511
Failure to thrive	44.18	11.39	43	56544	6527	56228953
Injection site pain	44.11	11.39	32	56555	117086	56118394
Folliculitis	43.55	11.39	3	56584	54976	56180504
Coma	42.57	11.39	5	56582	59650	56175830
Injection site erythema	41.62	11.39	13	56574	77435	56158045
Irritable bowel syndrome	41.54	11.39	9	56578	68449	56167031
Weight decreased	41.25	11.39	396	56191	240318	55995162
Pneumonia	41.10	11.39	605	55982	406493	55828987
Pneumonitis	40.95	11.39	95	56492	31469	56204011
General physical health deterioration	40.33	11.39	68	56519	169942	56065538
Musculoskeletal stiffness	40.23	11.39	59	56528	155948	56079532
Palmar-plantar erythrodysaesthesia syndrome	39.79	11.39	74	56513	20991	56214489
Hair colour changes	38.31	11.39	28	56559	2867	56232613
Paradoxical drug reaction	37.59	11.39	31	56556	3789	56231691
Intentional overdose	37.39	11.39	11	56576	68106	56167374
Off label use	37.09	11.39	369	56218	555811	55679669
Back pain	36.68	11.39	382	56205	236788	55998692
Blood potassium decreased	35.30	11.39	102	56485	38570	56196910
Blood creatine increased	35.05	11.39	34	56553	5139	56230341
Anaemia	35.05	11.39	417	56170	267094	55968386
Hypersensitivity	34.93	11.39	136	56451	256272	55979208
Haemoglobin decreased	34.48	11.39	242	56345	133895	56101585
Alopecia areata	33.62	11.39	20	56567	1447	56234033
Hypokalaemia	33.44	11.39	185	56402	94252	56141228
Hair texture abnormal	33.01	11.39	29	56558	3863	56231617
Sepsis	32.90	11.39	247	56340	139593	56095887
Skin exfoliation	32.41	11.39	96	56491	36804	56198676
Suicide attempt	32.37	11.39	9	56578	57827	56177653
Injection site reaction	32.31	11.39	7	56580	53240	56182240
Taste disorder	32.01	11.39	44	56543	9671	56225809
Hyponatraemia	30.92	11.39	192	56395	101947	56133533
Mucosal inflammation	30.84	11.39	104	56483	42706	56192774
Product use issue	30.55	11.39	91	56496	185950	56049530
Hypophagia	30.15	11.39	80	56507	28796	56206684
Oral pain	29.67	11.39	75	56512	26218	56209262
Rectal cancer metastatic	29.64	11.39	11	56576	268	56235212
Abdominal discomfort	29.49	11.39	161	56426	277113	55958367
Weight increased	29.29	11.39	125	56462	229578	56005902
Fibromyalgia	28.64	11.39	12	56575	59591	56175889
Knee arthroplasty	28.58	11.39	5	56582	44254	56191226
Exposure during pregnancy	28.38	11.39	59	56528	136283	56099197
Hip arthroplasty	28.16	11.39	3	56584	38620	56196860
Ill-defined disorder	28.14	11.39	17	56570	68526	56166954
C-reactive protein increased	27.72	11.39	23	56564	78661	56156819
Laboratory test abnormal	27.41	11.39	70	56517	24625	56210855
Dysgeusia	27.38	11.39	97	56490	40818	56194662
Red cell distribution width increased	27.37	11.39	40	56547	9300	56226180
Muscle twitching	26.93	11.39	54	56533	16188	56219292
Gastric disorder	26.92	11.39	84	56503	33126	56202354
Arthralgia	26.31	11.39	351	56236	501318	55734162
Red blood cell sedimentation rate increased	26.30	11.39	3	56584	36620	56198860
Hypoxia	25.77	11.39	115	56472	53782	56181698
Overdose	25.39	11.39	42	56545	105788	56129692
Deep vein thrombosis	24.75	11.39	147	56440	76830	56158650
Pyrexia	24.23	11.39	571	56016	418202	55817278
Lymphadenopathy	24.02	11.39	84	56503	35124	56200356
Injection site swelling	23.98	11.39	7	56580	43571	56191909
Impaired healing	23.21	11.39	32	56555	86809	56148671
Dry skin	22.88	11.39	101	56486	47008	56188472
Loss of personal independence in daily activities	22.75	11.39	29	56558	81340	56154140
Liver injury	22.53	11.39	7	56580	41841	56193639
Drug hypersensitivity	22.45	11.39	395	56192	274810	55960670
Cholestasis of pregnancy	21.73	11.39	14	56573	1167	56234313
Extrapyramidal disorder	21.60	11.39	42	56545	12314	56223166
Tumour marker increased	21.50	11.39	24	56563	4269	56231211
Foetal exposure during pregnancy	21.45	11.39	4	56583	33819	56201661
Mental status changes	21.02	11.39	84	56503	37417	56198063
Pulmonary embolism	20.72	11.39	181	56406	106943	56128537
Autoimmune nephritis	20.43	11.39	9	56578	345	56235135
Alopecia	20.20	11.39	193	56394	293265	55942215
Asthma	20.10	11.39	53	56534	112717	56122763
Dysphagia	19.97	11.39	146	56441	81801	56153679
Skull fracture	19.49	11.39	12	56575	924	56234556
Chills	19.14	11.39	172	56415	102432	56133048
Cataract	18.53	11.39	101	56486	51146	56184334
Eating disorder	18.48	11.39	48	56539	17057	56218423
Madarosis	18.47	11.39	18	56569	2735	56232745
Plasma cell myeloma recurrent	18.36	11.39	18	56569	2756	56232724
Intentional product misuse	18.20	11.39	15	56572	51489	56183991
Anuria	18.20	11.39	38	56549	11722	56223758
Blood cholesterol increased	18.16	11.39	28	56559	72551	56162929
Injection site bruising	18.12	11.39	8	56579	38513	56196967
Embolism	18.01	11.39	29	56558	7335	56228145
Inflammation	17.91	11.39	26	56561	69045	56166435
Therapeutic response decreased	17.87	11.39	16	56571	52742	56182738
Enteritis	17.78	11.39	29	56558	7414	56228066
Abortion spontaneous	17.75	11.39	11	56576	43742	56191738
Acquired cystic kidney disease	17.67	11.39	5	56582	49	56235431
Lymphocyte count decreased	17.64	11.39	65	56522	27874	56207606
Drug interaction	17.56	11.39	131	56456	209624	56025856
Ovarian cancer recurrent	17.48	11.39	12	56575	1112	56234368
Haematocrit decreased	17.16	11.39	78	56509	36751	56198729
Nasopharyngitis	17.10	11.39	141	56446	220818	56014662
Bacteraemia	17.03	11.39	44	56543	15587	56219893
Psoriasis	16.95	11.39	43	56544	92649	56142831
Pregnancy	16.95	11.39	6	56581	33027	56202453
Coronary artery disease	16.85	11.39	5	56582	30791	56204689
Blood pressure fluctuation	16.58	11.39	10	56577	40350	56195130
Dizziness	16.57	11.39	495	56092	375645	55859835
Palpitations	16.55	11.39	163	56424	99509	56135971
Streptococcal bacteraemia	16.46	11.39	13	56574	1494	56233986
Injection site pruritus	16.38	11.39	11	56576	41920	56193560
Morbid thoughts	16.27	11.39	9	56578	567	56234913
Type 2 diabetes mellitus	16.13	11.39	14	56573	46848	56188632
Neurologic neglect syndrome	15.94	11.39	15	56572	2183	56233297
Intentional self-injury	15.75	11.39	3	56584	24989	56210491
Clostridium difficile colitis	15.74	11.39	48	56539	18690	56216790
Carotid artery thrombosis	15.68	11.39	15	56572	2229	56233251
Pancreatic carcinoma recurrent	15.38	11.39	5	56582	81	56235399
Urinary tract infection	15.13	11.39	332	56255	240181	55995299
Ascites	14.95	11.39	76	56511	37468	56198012
Parkinsonism	14.95	11.39	31	56556	9515	56225965
Multiple sclerosis relapse	14.76	11.39	14	56573	44889	56190591
Oesophagitis	14.73	11.39	39	56548	14018	56221462
Drug reaction with eosinophilia and systemic symptoms	14.72	11.39	6	56581	30298	56205182
Dyssomnia	14.64	11.39	4	56583	34	56235446
Systemic inflammatory response syndrome	14.60	11.39	22	56565	5256	56230224
Dyspepsia	14.59	11.39	138	56449	83333	56152147
Hypermagnesaemia	14.30	11.39	10	56577	955	56234525
Sedation	13.81	11.39	9	56578	34845	56200635
Breast cellulitis	13.59	11.39	8	56579	568	56234912
Diabetes mellitus	13.53	11.39	20	56567	52715	56182765
Lymph node pain	13.48	11.39	11	56576	1324	56234156
Prescribed overdose	13.38	11.39	3	56584	22293	56213187
Lethargy	13.31	11.39	93	56494	51348	56184132
Neutropenic colitis	13.17	11.39	15	56572	2728	56232752
Osteoporosis	13.10	11.39	20	56567	52032	56183448
Tremor neonatal	12.96	11.39	5	56582	136	56235344
Angina pectoris	12.85	11.39	59	56528	27917	56207563
Multiple sclerosis	12.72	11.39	6	56581	27796	56207684
Plasmacytoma	12.72	11.39	14	56573	2452	56233028
Liver iron concentration abnormal	12.71	11.39	4	56583	58	56235422
Sleep disorder	12.67	11.39	31	56556	67632	56167848
Osteoarthritis	12.65	11.39	40	56547	80256	56155224
Oesophageal ulcer	12.53	11.39	18	56569	4121	56231359
Abdominal infection	12.51	11.39	12	56575	1789	56233691
Hypomagnesaemia	12.43	11.39	54	56533	24961	56210519
Joint range of motion decreased	12.36	11.39	5	56582	25360	56210120
Full blood count abnormal	12.30	11.39	56	56531	26406	56209074
Sneezing	12.28	11.39	39	56548	15521	56219959
Wrong technique in product usage process	12.24	11.39	25	56562	58143	56177337
Depressed level of consciousness	12.09	11.39	24	56563	56409	56179071
Metastases to peritoneum	12.06	11.39	15	56572	2989	56232491
Acute myeloid leukaemia	12.01	11.39	41	56546	16931	56218549
Blood pressure systolic increased	12.00	11.39	14	56573	40822	56194658
Neutropenic sepsis	11.93	11.39	38	56549	15147	56220333
Medication error	11.92	11.39	15	56572	42320	56193160
Decreased eye contact	11.91	11.39	6	56581	312	56235168
Enterocolitis infectious	11.80	11.39	11	56576	1582	56233898
Fanconi syndrome	11.77	11.39	10	56577	1273	56234207
Immune effector cell-associated neurotoxicity syndrome	11.71	11.39	11	56576	1597	56233883
Hepatitis	11.71	11.39	11	56576	35430	56200050
Coma scale abnormal	11.68	11.39	19	56568	4844	56230636
Gastrointestinal injury	11.67	11.39	7	56580	514	56234966
Pica	11.62	11.39	3	56584	20	56235460
Lipase increased	11.61	11.39	27	56560	8952	56226528
Blood bilirubin increased	11.57	11.39	65	56522	33289	56202191
Cardiac failure	11.51	11.39	43	56544	82050	56153430

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	433.85	12.48	606	35132	121243	31540363
Nausea	248.31	12.48	835	34903	307112	31354494
Fatigue	208.62	12.48	836	34902	334370	31327236
Dehydration	141.08	12.48	371	35367	118740	31542866
Disease progression	132.77	12.48	306	35432	90158	31571448
Plasma cell myeloma	124.17	12.48	226	35512	56305	31605301
Death	112.58	12.48	742	34996	359827	31301779
Diarrhoea	103.83	12.48	715	35023	351694	31309912
Malignant neoplasm progression	103.74	12.48	256	35482	78742	31582864
Pneumonia	97.36	12.48	678	35060	334634	31326972
Vomiting	96.32	12.48	502	35236	223471	31438135
Decreased appetite	91.34	12.48	378	35360	152839	31508767
Drug abuse	79.14	12.48	5	35733	87753	31573853
White blood cell count decreased	77.91	12.48	246	35492	87152	31574454
Drug ineffective	73.41	12.48	217	35521	395356	31266250
Drug interaction	68.14	12.48	81	35657	208462	31453144
Neuropathy peripheral	64.73	12.48	210	35528	75439	31586167
Toxicity to various agents	63.09	12.48	67	35671	181420	31480186
Condition aggravated	61.07	12.48	57	35681	163952	31497654
Constipation	58.82	12.48	286	35452	123705	31537901
Full blood count decreased	58.14	12.48	82	35656	16458	31645148
Platelet count decreased	56.20	12.48	260	35478	110175	31551431
Neutropenia	49.13	12.48	298	35440	140066	31521540
Hospice care	47.92	12.48	44	35694	5532	31656074
Completed suicide	47.27	12.48	22	35716	91492	31570114
Meconium abnormal	46.93	12.48	12	35726	67	31661539
Overdose	42.74	12.48	21	35717	84643	31576963
Neutrophil count decreased	41.66	12.48	131	35607	46263	31615343
Failure to thrive	41.47	12.48	48	35690	7914	31653692
Rash	39.93	12.48	374	35364	201112	31460494
Small intestinal obstruction	39.03	12.48	61	35677	13411	31648195
Neoplasm progression	37.01	12.48	75	35663	20197	31641409
Cytokine release syndrome	35.81	12.48	66	35672	16576	31645030
Product use in unapproved indication	35.09	12.48	36	35702	99135	31562471
Back pain	34.95	12.48	227	35511	109186	31552420
Necrotising enterocolitis neonatal	33.83	12.48	12	35726	227	31661379
Psoriasis	33.67	12.48	6	35732	46713	31614893
Asthenia	33.58	12.48	394	35344	224361	31437245
Therapeutic product effect incomplete	32.86	12.48	5	35733	43691	31617915
Rheumatoid arthritis	32.65	12.48	7	35731	47802	31613804
Sepsis	30.55	12.48	283	35455	151646	31509960
Intentional overdose	30.52	12.48	5	35733	41384	31620222
Deep vein thrombosis	28.67	12.48	140	35598	60596	31601010
Muscle spasms	28.42	12.48	152	35586	68166	31593440
Suicide attempt	26.38	12.48	5	35733	37243	31624363
Adverse drug reaction	26.24	12.48	75	35663	25126	31636480
Coma	26.18	12.48	7	35731	41143	31620463
Bacteraemia	26.18	12.48	60	35678	17574	31644032
Bradycardia	25.87	12.48	24	35714	69303	31592303
Intentional product misuse	25.02	12.48	6	35732	37945	31623661
Thrombosis	24.94	12.48	109	35629	45042	31616564
Rhabdomyolysis	24.94	12.48	21	35717	63560	31598046
General physical health deterioration	24.90	12.48	57	35681	113378	31548228
Off label use	24.52	12.48	262	35476	347012	31314594
Cardiac failure	24.33	12.48	37	35701	85916	31575690
Ageusia	23.96	12.48	40	35698	9291	31652315
Injection site pain	23.79	12.48	5	35733	34629	31626977
Pulmonary embolism	23.42	12.48	165	35573	81481	31580125
Oral pain	22.63	12.48	40	35698	9725	31651881
Laboratory test abnormal	22.59	12.48	59	35679	18755	31642851
Dysgeusia	21.73	12.48	67	35671	23399	31638207
C-reactive protein increased	20.43	12.48	15	35723	48635	31612971
Immune effector cell-associated neurotoxicity syndrome	20.21	12.48	19	35719	2460	31659146
Hiccups	20.19	12.48	37	35701	9250	31652356
Spinal cord compression	20.06	12.48	23	35715	3754	31657852
Weight decreased	19.83	12.48	271	35467	159681	31501925
Coronary artery disease	19.62	12.48	14	35724	46073	31615533
Hypophagia	19.55	12.48	62	35676	21980	31639626
Clostridium difficile infection	19.54	12.48	53	35685	17226	31644380
Fluid imbalance	19.30	12.48	8	35730	234	31661372
Treatment failure	19.27	12.48	11	35727	40781	31620825
Wrong technique in product usage process	18.84	12.48	7	35731	33336	31628270
Pleural effusion	18.42	12.48	146	35592	74774	31586832
Hyponatraemia	18.24	12.48	144	35594	73655	31587951
Laparotomy	17.80	12.48	8	35730	286	31661320
Drug reaction with eosinophilia and systemic symptoms	17.48	12.48	6	35732	30012	31631594
Dystonia	16.53	12.48	36	35702	10189	31651417
Haematochezia	16.32	12.48	13	35725	40451	31621155
Inappropriate schedule of product administration	16.27	12.48	20	35718	50803	31610803
Diaphragmatic rupture	16.18	12.48	4	35734	19	31661587
Bacillus bacteraemia	15.75	12.48	5	35733	66	31661540
Enterocolitis infectious	15.67	12.48	13	35725	1427	31660179
Mental status changes	15.62	12.48	81	35657	35887	31625719
Asthma	15.60	12.48	15	35723	42596	31619010
Temperature intolerance	15.29	12.48	18	35720	3021	31658585
Mixed dementia	15.08	12.48	7	35731	270	31661336
Oesophagitis	14.97	12.48	39	35699	12377	31649229
Inferior vena caval occlusion	14.87	12.48	4	35734	28	31661578
Pneumonitis	14.70	12.48	71	35667	30581	31631025
Cholestasis	14.62	12.48	5	35733	25070	31636536
Hypoxia	14.60	12.48	102	35636	50211	31611395
Plasma cell myeloma recurrent	14.60	12.48	20	35718	3904	31657702
Blood potassium decreased	14.38	12.48	46	35692	16380	31645226
Therapeutic product effect decreased	14.27	12.48	9	35729	31613	31629993
Therapeutic response decreased	14.26	12.48	6	35732	26503	31635103
Red blood cell count decreased	14.26	12.48	64	35674	26743	31634863
Drug dependence	14.06	12.48	4	35734	22575	31639031
Anaemia	13.99	12.48	327	35411	213195	31448411
Pancytopenia	13.85	12.48	155	35583	87161	31574445
Hair colour changes	13.81	12.48	13	35725	1687	31659919
Peripheral swelling	13.40	12.48	126	35612	67739	31593867
Wrist deformity	13.25	12.48	7	35731	358	31661248
Electrocardiogram QT prolonged	13.19	12.48	14	35724	37973	31623633
Seizure	13	12.48	63	35675	99705	31561901
Eosinophilia	12.94	12.48	5	35733	23248	31638358
Aggression	12.66	12.48	14	35724	37277	31624329
Cytomegalovirus infection	12.65	12.48	6	35732	24701	31636905
Epilepsy	12.61	12.48	4	35734	21037	31640569
Tooth disorder	12.60	12.48	32	35706	9997	31651609
Abdominal distension	12.57	12.48	99	35639	50585	31611021
Oral candidiasis	12.55	12.48	34	35704	11043	31650563
Medication error	12.50	12.48	5	35733	22767	31638839

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	884.40	11.30	1075	72770	203243	70651356
Nausea	520.66	11.30	1999	71846	850089	70004510
Dehydration	344.62	11.30	740	73105	225402	70629197
Disease progression	343.29	11.30	598	73247	156074	70698525
Drug ineffective	266.16	11.30	355	73490	939397	69915202
Vomiting	260.39	11.30	1262	72583	591849	70262750
Fatigue	257.38	11.30	1598	72247	822721	70031878
Diarrhoea	245.95	11.30	1521	72324	781820	70072779
White blood cell count decreased	236.59	11.30	537	73308	169604	70684995
Plasma cell myeloma	186.26	11.30	299	73546	72902	70781697
Platelet count decreased	162.36	11.30	480	73365	177742	70676857
Malignant neoplasm progression	154.61	11.30	371	73474	121368	70733231
Toxicity to various agents	143.20	11.30	113	73732	382059	70472540
Death	142.51	11.30	963	72882	509098	70345501
Neutropenia	127.56	11.30	568	73277	256588	70598011
Pneumonia	127.12	11.30	1056	72789	595176	70259423
Contraindicated product administered	125.74	11.30	3	73842	134609	70719990
Decreased appetite	124.92	11.30	637	73208	304143	70550456
Synovitis	120.25	11.30	3	73842	129225	70725374
Drug abuse	118.94	11.30	9	73836	147247	70707352
Constipation	118.79	11.30	549	73296	251889	70602710
Rheumatoid arthritis	116.06	11.30	81	73764	291724	70562875
Neutrophil count decreased	111.86	11.30	260	73585	83296	70771303
Neoplasm progression	104.57	11.30	177	73668	45051	70809548
Asthenia	101.90	11.30	819	73026	456847	70397752
Arthropathy	97.32	11.30	19	73826	150038	70704561
Completed suicide	95.78	11.30	59	73786	227076	70627523
Therapeutic product effect decreased	95.13	11.30	17	73828	143001	70711598
Condition aggravated	93.87	11.30	190	73655	427445	70427154
Small intestinal obstruction	89.26	11.30	119	73726	24536	70830063
Failure to thrive	88.07	11.30	80	73765	10749	70843850
Therapeutic product effect incomplete	84.80	11.30	12	73833	119870	70734729
Cytokine release syndrome	84.17	11.30	120	73725	26347	70828252
Joint swelling	82.63	11.30	85	73760	253126	70601473
Hospice care	81.63	11.30	68	73777	8137	70846462
Blood magnesium decreased	80.58	11.30	88	73757	14753	70839846
Sepsis	79.31	11.30	480	73365	244065	70610534
Systemic lupus erythematosus	77.48	11.30	8	73837	101894	70752705
Off label use	76.21	11.30	458	73387	742602	70111997
Full blood count decreased	75.41	11.30	108	73737	23810	70830789
Pleural effusion	73.10	11.30	303	73542	132561	70722038
Abdominal pain	72.12	11.30	605	73240	341522	70513077
Clostridium difficile infection	71.96	11.30	138	73707	38678	70815921
Neovascularisation	71.21	11.30	31	73814	1114	70853485
Thrombosis	69.42	11.30	204	73641	75201	70779398
Neuropathy peripheral	66.39	11.30	285	73560	126611	70727988
Coma	65.40	11.30	9	73836	91835	70762764
Drug interaction	61.59	11.30	198	73647	381243	70473356
Drug intolerance	60.69	11.30	88	73757	225599	70629000
Intentional overdose	60.67	11.30	14	73831	98421	70756178
Injection site pain	57.80	11.30	25	73820	117594	70737005
Overdose	56.47	11.30	56	73789	169689	70684910
Heart rate abnormal	54.58	11.30	46	73799	5593	70849006
Pancytopenia	54.39	11.30	305	73540	150802	70703797
General physical health deterioration	54.19	11.30	102	73743	235929	70618670
Colitis	50.69	11.30	164	73681	63650	70790949
Back pain	49.59	11.30	465	73380	270687	70583912
Carbohydrate antigen 125 increased	49.34	11.30	29	73816	1981	70852618
Hair colour changes	48.63	11.30	37	73808	3886	70850713
Thrombocytopenia	48.29	11.30	419	73426	238691	70615908
Gangrene	48.15	11.30	51	73794	8258	70846341
Hyponatraemia	47.94	11.30	308	73537	159779	70694820
Pneumonitis	47.68	11.30	145	73700	54452	70800147
Suicide attempt	47.64	11.30	12	73833	79498	70775101
Arterial occlusive disease	47.51	11.30	49	73796	7693	70846906
Pericarditis	46.65	11.30	15	73830	84690	70769909
Red blood cell count decreased	45.99	11.30	139	73706	52022	70802577
Hypophagia	44.68	11.30	119	73726	41451	70813148
Akathisia	43.98	11.30	59	73786	12234	70842365
Lymphadenitis	42.79	11.30	35	73810	4082	70850517
Palmar-plantar erythrodysaesthesia syndrome	42.53	11.30	96	73749	30151	70824448
Bacteraemia	42.30	11.30	94	73751	29215	70825384
C-reactive protein increased	42.16	11.30	32	73813	110485	70744114
Pulmonary embolism	41.93	11.30	292	73553	155575	70699024
Deep vein thrombosis	41.19	11.30	226	73619	110816	70743783
Lower respiratory tract infection	40.69	11.30	34	73811	111879	70742720
Oral pain	40.58	11.30	92	73753	28974	70825625
Musculoskeletal stiffness	39.32	11.30	58	73787	147702	70706897
Hypoxia	38.75	11.30	196	73649	93148	70761451
Anaemia	38.65	11.30	612	73233	402811	70451788
Glossodynia	38.50	11.30	21	73824	86466	70768133
Psoriatic arthropathy	38.37	11.30	10	73835	64761	70789838
Dysgeusia	38.22	11.30	126	73719	49376	70805223
Hepatic enzyme increased	37.66	11.30	66	73779	156924	70697675
Weight decreased	36.85	11.30	489	73356	309999	70544600
Mental status changes	36.33	11.30	146	73699	62955	70791644
Discomfort	35.96	11.30	34	73811	105402	70749197
Intentional product misuse	35.91	11.30	19	73826	79576	70775023
Immune effector cell-associated neurotoxicity syndrome	33.55	11.30	30	73815	3948	70850651
Wound	33.48	11.30	32	73813	98700	70755899
Pyrexia	33.36	11.30	847	72998	606105	70248494
Treatment failure	33.32	11.30	62	73783	144080	70710519
Folliculitis	33.25	11.30	3	73842	42567	70812032
Blood potassium decreased	32.77	11.30	108	73737	42313	70812286
Haemoglobin decreased	32.70	11.30	342	73503	204817	70649782
Swelling	32.42	11.30	95	73750	188444	70666155
Injection site erythema	32.04	11.30	18	73827	72906	70781693
Asthma	31.57	11.30	48	73797	120745	70733854
Blood pressure fluctuation	31.53	11.30	11	73834	59001	70795598
Coronary artery disease	31.35	11.30	13	73832	62723	70791876
Alopecia areata	30.97	11.30	20	73825	1616	70852983
Mobility decreased	30.90	11.30	37	73808	102962	70751637
Injection site reaction	30.89	11.30	7	73838	49845	70804754
Oesophagitis	30.85	11.30	71	73774	22581	70832018
Drug reaction with eosinophilia and systemic symptoms	30.68	11.30	11	73834	58002	70796597
Mucosal inflammation	30.68	11.30	146	73699	67704	70786895
Hypersensitivity	30.66	11.30	129	73716	229683	70624916
Weight increased	30.52	11.30	139	73706	242192	70612407
Dry skin	30.29	11.30	127	73718	55804	70798795
Nasopharyngitis	29.47	11.30	125	73720	222081	70632518
Red blood cell sedimentation rate increased	29.45	11.30	3	73842	38639	70815960
Hair texture abnormal	28.86	11.30	25	73820	3155	70851444
Rectal cancer metastatic	28.60	11.30	13	73832	518	70854081
Enterocolitis infectious	28.20	11.30	23	73822	2671	70851928
Infusion related reaction	27.52	11.30	109	73736	197425	70657174
Rhabdomyolysis	27.06	11.30	36	73809	95724	70758875
Injection site swelling	26.86	11.30	6	73839	43151	70811448
Cardiac failure	26.40	11.30	70	73775	143471	70711128
Taste disorder	25.57	11.30	44	73801	11341	70843258
Pain	25.29	11.30	482	73363	628334	70226265
Knee arthroplasty	25.29	11.30	3	73842	34298	70820301
Bradycardia	25.08	11.30	58	73787	124557	70730042
Inflammation	24.96	11.30	27	73818	78638	70775961
Red cell distribution width increased	24.63	11.30	48	73797	13609	70840990
Product use in unapproved indication	24.37	11.30	122	73723	207356	70647243
Eosinophilia	24.31	11.30	6	73839	40313	70814286
Dysphagia	23.94	11.30	200	73645	112634	70741965
Embolism	23.85	11.30	46	73799	12942	70841657
Hypokalaemia	23.45	11.30	224	73621	130964	70723635
Psoriasis	23.04	11.30	42	73803	98391	70756208
Loss of personal independence in daily activities	22.91	11.30	33	73812	84877	70769722
Sedation	22.84	11.30	10	73835	46721	70807878
Paradoxical drug reaction	22.45	11.30	31	73814	6605	70847994
Hepatitis	22.44	11.30	12	73833	49968	70804631
Medication error	22.32	11.30	16	73829	56896	70797703
Systemic inflammatory response syndrome	22.25	11.30	40	73805	10672	70843927
Cytomegalovirus infection	21.96	11.30	7	73838	39751	70814848
Enteritis	21.81	11.30	44	73801	12787	70841812
Performance status decreased	21.77	11.30	28	73817	5573	70849026
Muscle twitching	21.55	11.30	57	73788	19770	70834829
Lymphocyte count decreased	21.39	11.30	96	73749	43443	70811156
Blood pressure systolic increased	21.30	11.30	17	73828	57242	70797357
Cholestasis of pregnancy	21.24	11.30	13	73832	956	70853643
Heart rate decreased	21.14	11.30	20	73825	61995	70792604
Impaired healing	20.97	11.30	28	73817	74346	70780253
Therapeutic response decreased	20.94	11.30	18	73827	58435	70796164
Ageusia	20.70	11.30	47	73798	14815	70839784
Ill-defined disorder	20.68	11.30	16	73829	54725	70799874
Intentional self-injury	20.52	11.30	4	73841	31646	70822953
Irritable bowel syndrome	20.33	11.30	14	73831	50836	70803763
Arthralgia	20.17	11.30	386	73459	503004	70351595
Dizziness	19.94	11.30	628	73217	463513	70391086
Gastric disorder	19.90	11.30	78	73767	33244	70821355
Product use issue	19.90	11.30	108	73737	179829	70674770
Blood creatine increased	19.85	11.30	34	73811	8730	70845869
Depressed level of consciousness	19.85	11.30	38	73807	87393	70767206
Streptococcal bacteraemia	19.43	11.30	20	73825	3133	70851466
Fibromyalgia	19.38	11.30	13	73832	47861	70806738
Madarosis	19.27	11.30	18	73827	2505	70852094
Wrong technique in product usage process	19.23	11.30	26	73819	68672	70785927
Non-small cell lung cancer	19.04	11.30	28	73817	6319	70848280
Haematocrit decreased	18.90	11.30	113	73732	57145	70797454
Osteoporosis	18.85	11.30	14	73831	48893	70805706
Hypophosphataemia	18.84	11.30	48	73797	16278	70838321
Hypermagnesaemia	18.79	11.30	13	73832	1178	70853421
Skin exfoliation	18.71	11.30	100	73745	48526	70806073
Klebsiella bacteraemia	18.50	11.30	18	73827	2636	70851963
Clostridium difficile colitis	18.24	11.30	69	73776	28927	70825672
Liver injury	18.21	11.30	10	73835	41025	70813574
Cholestasis	18.07	11.30	14	73831	47858	70806741
Exposure during pregnancy	17.51	11.30	41	73804	87676	70766923
Injection site bruising	17.27	11.30	9	73836	38023	70816576
Metastatic renal cell carcinoma	17.16	11.30	18	73827	2882	70851717
Cancer pain	16.84	11.30	23	73822	4851	70849748
Acquired cystic kidney disease	16.81	11.30	5	73840	57	70854542
Stress	16.81	11.30	28	73817	67938	70786661
Cholangitis	16.62	11.30	37	73808	11512	70843087
Maternal exposure during pregnancy	16.47	11.30	63	73782	115282	70739317
Tumour marker increased	16.39	11.30	20	73825	3774	70850825
Therapy non-responder	16.12	11.30	35	73810	76880	70777719
Injury	16.03	11.30	27	73818	65218	70789381
Dystonia	15.96	11.30	51	73794	19655	70834944
Chills	15.90	11.30	225	73620	144561	70710038
Cardiogenic shock	15.89	11.30	9	73836	36298	70818301
Hypoglycaemia	15.88	11.30	48	73797	94316	70760283
Atrial fibrillation	15.88	11.30	275	73570	184073	70670526
Abdominal infection	15.84	11.30	18	73827	3151	70851448
Anaphylactic shock	15.80	11.30	7	73838	32483	70822116
Diabetes mellitus	15.63	11.30	32	73813	71792	70782807
Myelosuppression	15.46	11.30	6	73839	30139	70824460
Autoimmune nephritis	15.46	11.30	9	73836	604	70853995
Retching	15.44	11.30	44	73801	15935	70838664
Injection site pruritus	15.40	11.30	11	73834	39199	70815400
Fluid imbalance	15.39	11.30	8	73837	429	70854170
Hip arthroplasty	15.38	11.30	5	73840	28035	70826564
Mixed dementia	15.31	11.30	7	73838	283	70854316
Drug dependence	15.29	11.30	10	73835	37311	70817288
Eating disorder	15.00	11.30	48	73797	18517	70836082
Multiple sclerosis	14.79	11.30	4	73841	25281	70829318
Spinal cord compression	14.77	11.30	24	73821	5904	70848695
Inferior vena caval occlusion	14.61	11.30	4	73841	33	70854566
Neurologic neglect syndrome	14.48	11.30	15	73830	2366	70852233
Urinary tract infection	14.44	11.30	350	73495	248419	70606180
Lymph node pain	14.44	11.30	12	73833	1431	70853168
Diabetes mellitus inadequate control	14.39	11.30	3	73842	22642	70831957
Chorioretinitis	14.04	11.30	10	73835	949	70853650
Inappropriate schedule of product administration	13.94	11.30	61	73784	107494	70747105
Colon cancer metastatic	13.92	11.30	14	73831	2134	70852465
Hyperglycaemia	13.91	11.30	115	73730	64557	70790042
Oral candidiasis	13.78	11.30	57	73788	24895	70829704
Agranulocytosis	13.73	11.30	13	73832	40285	70814314
Obstructive airways disorder	13.72	11.30	5	73840	26108	70828491
Carotid artery thrombosis	13.65	11.30	15	73830	2531	70852068
Blood sodium decreased	13.50	11.30	66	73779	30932	70823667
Pneumothorax	13.46	11.30	58	73787	25788	70828811
Lymphadenopathy	13.45	11.30	92	73753	48699	70805900
Stomatitis	13.43	11.30	198	73647	128313	70726286
Skull fracture	13.41	11.30	12	73833	1580	70853019
Multiple sclerosis relapse	13.38	11.30	15	73830	43002	70811597
Hypogeusia	13.30	11.30	12	73833	1597	70853002
Arthritis infective	13.30	11.30	26	73819	7386	70847213
Oesophageal ulcer	13.17	11.30	24	73821	6470	70848129
Haematochezia	13.16	11.30	36	73809	73045	70781554
Bacillus bacteraemia	13.15	11.30	5	73840	126	70854473
Type 2 diabetes mellitus	13.04	11.30	16	73829	44064	70810535
Palpitations	12.92	11.30	174	73671	110579	70744020
Fear	12.74	11.30	3	73842	20808	70833791
Metastases to liver	12.66	11.30	57	73788	25821	70828778
Respiratory arrest	12.63	11.30	23	73822	53910	70800689
Hypovolaemia	12.60	11.30	41	73804	15952	70838647
Liver iron concentration abnormal	12.57	11.30	4	73841	58	70854541
Muscular weakness	12.50	11.30	208	73637	138128	70716471
Hypoalbuminaemia	12.44	11.30	46	73799	19076	70835523
Lung squamous cell carcinoma metastatic	12.39	11.30	4	73841	61	70854538
Blood cholesterol increased	12.26	11.30	31	73814	64573	70790026
Oxygen saturation decreased	12.26	11.30	71	73774	116358	70738241
Feeding disorder	12.25	11.30	38	73807	14418	70840181
Mean cell haemoglobin concentration decreased	12.16	11.30	18	73827	4085	70850514
Dyspepsia	12.12	11.30	144	73701	88933	70765666
Joint range of motion decreased	12.05	11.30	6	73839	26020	70828579
Urticaria	12.05	11.30	110	73735	162939	70691660
Drug eruption	12.04	11.30	14	73831	39482	70815117
Pancreatic carcinoma recurrent	12.03	11.30	5	73840	160	70854439
Confusional state	11.97	11.30	384	73461	284014	70570585
Aggression	11.94	11.30	20	73825	48426	70806173
Hiccups	11.92	11.30	28	73817	9024	70845575
Psychotic disorder	11.89	11.30	13	73832	37688	70816911
Pregnancy	11.76	11.30	5	73840	23776	70830823
Pancreatic carcinoma metastatic	11.61	11.30	17	73828	3823	70850776
Aphasia	11.60	11.30	81	73764	43168	70811431
Muscle spasms	11.58	11.30	225	73620	153821	70700778
Blood bilirubin increased	11.56	11.30	104	73741	59797	70794802
Epilepsy	11.55	11.30	14	73831	38770	70815829
Prescribed overdose	11.52	11.30	7	73838	27174	70827425
Acute myeloid leukaemia	11.48	11.30	63	73782	30877	70823722
Renal cell carcinoma	11.42	11.30	24	73821	7177	70847422
Lymphatic disorder	11.42	11.30	6	73839	329	70854270
Myocardial infarction	11.34	11.30	119	73726	171526	70683073
Morbid thoughts	11.34	11.30	8	73837	748	70853851
Therapeutic drug monitoring analysis incorrectly performed	11.30	11.30	6	73839	336	70854263

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AB04	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure
FDA CS	M0016525	Phenothiazines
MeSH PA	D000932	Antiemetics
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:48561	dopaminergic antagonists
CHEBI has role	CHEBI:48873	acetylcholine receptor antagonist
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:65190	typical antipsychotic drugs
CHEBI has role	CHEBI:76779	post-proline endopeptidase inhibitors
CHEBI has role	CHEBI:131787	D2R antagonist
FDA EPC	N0000175746	Phenothiazine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Schizophrenia	indication	58214004	DOID:5419
Nonpsychotic Anxiety	indication
Prolonged-Severe Nausea and Vomiting	indication
Migraine	off-label use	37796009	DOID:6364
Chemotherapy-induced nausea and vomiting	off-label use	236084000
Brain damage	contraindication	2470005
Tachyarrhythmia	contraindication	6285003
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Severe chronic ulcerative colitis	contraindication	14311001
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Toxic megacolon	contraindication	28536002	DOID:1770
Orthostatic hypotension	contraindication	28651003
Atony of colon	contraindication	29479008
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Conduction disorder of the heart	contraindication	44808001
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Ulcerative colitis	contraindication	64766004	DOID:8577
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Extrapyramidal disease	contraindication	76349003
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Hyperglycemia	contraindication	80394007	DOID:4195
Hiatal hernia	contraindication	84089009	DOID:12642
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Gastrointestinal obstruction	contraindication	126765001
Acute disease of cardiovascular system	contraindication	128487001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Angina pectoris	contraindication	194828000
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Drowsy	contraindication	271782001
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Visual impairment	contraindication	397540003
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Gastrointestinal disturbances associated with emotional stress	Indication
Dogs	Gastrointestinal disturbances associated with emotional stress	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Darbazine Spansule Capsule No.1	Zoetis Inc.	2
Darbazine Injectable	Zoetis Inc.	2
Neo-Darbazine Spansule Capsule No.1, Neo-Darbazine Spansule Capsule No.3	Zoetis Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.74	Basic
pKa2	4.74	Basic
pKa3	2.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	8.76	WOMBAT-PK	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	Ki	8.61	WOMBAT-PK	IUPHAR
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	7.20	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.64	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.82	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.21	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.40	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.23	PDSP
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.82	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.19	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.91	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.91	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.62	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	8.32	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	7.72	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.61	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.96	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.49	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.72	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.80	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.92	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.86	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.52	DRUG MATRIX
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	7.17	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.89	DRUG MATRIX
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		IC50	5.70	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.25	DRUG MATRIX
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.30	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.11	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.31	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	5.92	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.38	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.49	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.02	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_CAVPO		Ki	6.71	DRUG MATRIX
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.77	CHEMBL

External reference:

ID	Source
4018001	VUID
N0000146346	NUI
D00479	KEGG_DRUG
84-02-6	SECONDARY_CAS_RN
1257-78-9	SECONDARY_CAS_RN
4017999	VANDF
4018000	VANDF
4018001	VANDF
C0033229	UMLSCUI
CHEBI:8435	CHEBI
CHEMBL728	ChEMBL_ID
DB00433	DRUGBANK_ID
CHEMBL1200587	ChEMBL_ID
CHEMBL1314751	ChEMBL_ID
CHEMBL1201154	ChEMBL_ID
D011346	MESH_DESCRIPTOR_UI
4917	PUBCHEM_CID
7279	IUPHAR_LIGAND_ID
699	INN_ID
YHP6YLT61T	UNII
235739	RXNORM
2073	MMSL
5361	MMSL
5362	MMSL
5363	MMSL
6416	MMSL
6417	MMSL
d00355	MMSL
001478	NDDF
001479	NDDF
001480	NDDF
003466	NDDF
22827004	SNOMEDCT_US
372853006	SNOMEDCT_US
3823007	SNOMEDCT_US
395843006	SNOMEDCT_US
79129001	SNOMEDCT_US
P77	PDB_CHEM_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5105	TABLET, FILM COATED	5 mg	ORAL	ANDA	14 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5110	TABLET, FILM COATED	10 mg	ORAL	ANDA	14 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	0440-8190	TABLET	5 mg	ORAL	ANDA	12 sections
Compro	HUMAN PRESCRIPTION DRUG LABEL	1	0574-7226	SUPPOSITORY	25 mg	RECTAL	ANDA	19 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6135	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6135	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0135	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections
Prochlorperazine	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0135	SUPPOSITORY	25 mg	RECTAL	ANDA	13 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0351	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0351	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5020	TABLET, FILM COATED	5 mg	ORAL	ANDA	18 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5021	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-281	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-511	TABLET	5 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	14789-700	INJECTION	5 mg	INTRAMUSCULAR	ANDA	18 sections
PROCHLORPERAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-327	TABLET	10 mg	ORAL	ANDA	10 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-571	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-572	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-294	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-497	INJECTION	5 mg	INTRAMUSCULAR	ANDA	12 sections
Prochlorperazine Edisylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-523	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
PROCHLORPERAZINE EDISYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	25021-790	INJECTION	5 mg	INTRAVENOUS	ANDA	18 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-141	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-550	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-728	TABLET	5 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	42291-729	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	42708-103	TABLET	10 mg	ORAL	ANDA	12 sections
Prochlorperazine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	43063-353	TABLET, FILM COATED	5 mg	ORAL	ANDA	14 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-742	TABLET	10 mg	ORAL	ANDA	12 sections
PROCHLORPERAZINE MALEATE	HUMAN PRESCRIPTION DRUG LABEL	1	43063-742	TABLET	10 mg	ORAL	ANDA	12 sections